BMO Lifts AbbVie Inc. (ABBV) Price Target to $240 After Rinvoq Litigation Win [Yahoo! Finance]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: Yahoo! Finance
analyst at BMO Capital, increased the price target on AbbVie Inc. (NYSE:ABBV) to $240 from $215 with an ‘Outperform' rating. This potential upside of nearly 10% follows the company's announcement that it has resolved litigation with generic drugmakers, allowing for the early market entry of generic Rinvoq. Many believe that generic competition market entry won't occur until 2037, four years after the 2033 expiration of the composition of matter patent. This will not only aid AbbVie Inc. (NYSE:ABBV) in surpassing expectations but also make it a top biotech pick. Even today, if we consider the year-to-date return delivered by the company, it outperforms the market by a healthy 14.31%. AbbVie (ABBV)'s Dividend Track Record: How It Became a Leader in Consistent Dividends From the EU-US deal on pharmaceuticals and expansion of its neuroscience portfolio through Gilgamesh's bretisilocin acquisition to an overall improved guidance, there's no doubt the company is among the best stocks
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- Top Stock Reports for AbbVie, Coca-Cola & Chevron [Yahoo! Finance]Yahoo! Finance
- 2 Dividend Kings Quietly Beating the Market This Year [Yahoo! Finance]Yahoo! Finance
- What AbbVie (ABBV)'s Restructured OSE Immunology Partnership Means For Shareholders [Yahoo! Finance]Yahoo! Finance
- ????????????????????????????2035????128???????????? [CNET News]CNET News
- Vanguard Health Care Fund's Strategic Moves: Spotlight on AbbVie Inc [Yahoo! Finance]Yahoo! Finance
ABBV
Earnings
- 10/31/25 - Beat
ABBV
Sec Filings
- 11/20/25 - Form F-6
- 11/4/25 - Form 10-Q
- 10/31/25 - Form 8-K
- ABBV's page on the SEC website